Business context and reporting period
Transgenomic, Inc. filed this unaudited Form 10-Q for the quarter and six months ended June 30, 2015. The filing describes two segments: Laboratory Services, including genetic testing and biomarker research, and Genetic Assays and Platforms, which sells instruments and consumables. The company highlighted its MX-ICP technology and plans to commercialize cancer testing applications. The request metadata names Precipio, Inc.; the filing itself names Transgenomic, Inc., so the issuer identity should be verified.
Financial results and liquidity
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Net sales | $7.04 million | $6.76 million | $13.55 million | $13.02 million |
| Gross profit / margin | $2.87 million / 41% | $2.39 million / 35% | $5.85 million / 43% | $4.89 million / 38% |
| Operating loss | $2.78 million | $3.96 million | $5.42 million | $7.49 million |
| Net loss | $3.28 million | $3.89 million | $6.32 million | $8.07 million |
| Net loss available to common stockholders | $3.61 million | $4.20 million | $6.98 million | $8.60 million |
- At June 30, cash and cash equivalents were $2.31 million; working capital was $2.16 million, versus $2.32 million at year-end 2014.
- Total debt was $7.68 million, including $2.83 million current maturities. Debt included a $3.0 million revolving line, $4.0 million term loan and $0.68 million convertible notes.
- For the first half, operating cash use was $6.01 million, investing cash use was $0.24 million, and financing provided $6.95 million; cash increased $0.70 million.
- Net accounts receivable was $9.72 million, with an $8.43 million allowance for doubtful accounts. The first-half provision for doubtful accounts was $1.91 million.
Material changes versus prior comparable periods
- Q2 and first-half sales each rose 4%. Laboratory Services grew 26% in Q2 and 29% in the first half; Genetic Assays and Platforms fell 25% and 30%, respectively.
- Laboratory Services drove gross-margin improvement: segment margin was 54% in Q2 versus 39% a year earlier, and 55% versus 41% for the first half. Genetic Assays and Platforms margin fell to 11% in Q2 and 13% for the first half, from 31% and 32%, respectively.
- Operating losses narrowed, reflecting higher gross profit and lower selling, general and administrative and research and development expenses. First-half cash used in operations also improved from $7.26 million to $6.01 million, though remained substantial.
- First-half financing included approximately $6.2 million net proceeds from a common-stock offering and $0.9 million from convertible notes. Common shares outstanding increased to 12.33 million at June 30 from 8.08 million at December 31, 2014.
Outlook, risks, contingencies and unusual items
- Going concern: Management stated that recurring losses and operating cash use, together with dependence on revenue growth, improved collections, potential asset sales or additional financing, raise substantial doubt about the company’s ability to continue as a going concern. No assurance was given that financing would be available on acceptable terms or at all.
- Debt covenant issue: The company was not in compliance at June 30 with the revolving-line borrowing-base restriction. On August 10, 2015, it paid lenders $0.7 million and obtained a waiver, restoring compliance. The term loan’s principal payments were deferred until April 1, 2016 under an April 2015 amendment; the company reported compliance with financial covenants at quarter-end.
- Subsequent financing: A July 7, 2015 offering generated approximately $3.0 million gross proceeds through common shares and warrants, including immediately exercisable warrants with a $0.01 exercise price. This is a potential source of dilution; the filing does not state net proceeds in the cited discussion.
- Commercial outlook: Management announced plans for up to six additional MX-ICP-based cancer tests during 2015 and described a liquid-biopsy pilot with biopharmaceutical firms. These are plans and developments, not assured revenue or earnings guidance; the filing provides no quantitative financial forecast.
- Key operating risks: Collection and reimbursement uncertainty, customer budget constraints and competition, foreign-exchange exposure, and the need for additional capital. The filing notes a $0.3 million obsolete-inventory provision in the first half and non-cash warrant revaluation expense of $0.42 million.
- Controls and legal matters: Disclosure controls were deemed ineffective because material weaknesses remained in revenue-recognition timing and the allowance-for-doubtful-accounts process. Remediation was underway. Management said pending ordinary-course claims were not expected to have a material adverse effect.
Important facts for investors to verify
- Confirm that Transgenomic, Inc.—not Precipio, Inc.—is the intended issuer and filing.
- Assess cash runway, near-term obligations and the company’s ability to achieve its operating plan or obtain further financing.
- Review receivable aging, allowance adequacy, collections and reimbursement trends, given the large allowance and disclosed control weakness.
- Check the terms and subsequent exercise or conversion activity of the July 2015 financing, warrants and convertible notes, including dilution.
- Monitor lender compliance, borrowing-base availability and any further debt amendments or payments.
- Track whether MX-ICP launches and studies translate into commercial adoption and whether the declining Genetic Assays and Platforms business stabilizes.